These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 29909472)

  • 61. Persistent Sexual Dysfunction with Finasteride 1 mg Taken for Hair Loss.
    Guo M; Heran B; Flannigan R; Kezouh A; Etminan M
    Pharmacotherapy; 2016 Nov; 36(11):1180-1184. PubMed ID: 27644029
    [TBL] [Abstract][Full Text] [Related]  

  • 62. 5-alpha reductase inhibitors: New evidences on benefits and harms beyond benign prostatic hyperplasia.
    Alcántara Montero A; Müller-Arteaga C
    Actas Urol Esp (Engl Ed); 2019; 43(1):52-53. PubMed ID: 30032935
    [No Abstract]   [Full Text] [Related]  

  • 63. Finasteride and Suicide: A Postmarketing Case Series.
    Irwig MS
    Dermatology; 2020; 236(6):540-545. PubMed ID: 31935720
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
    Corona G; Rastrelli G; Maseroli E; Balercia G; Sforza A; Forti G; Mannucci E; Maggi M
    J Endocrinol Invest; 2012 Nov; 35(10):915-20. PubMed ID: 22777612
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
    Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
    Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
    Belknap SM; Aslam I; Kiguradze T; Temps WH; Yarnold PR; Cashy J; Brannigan RE; Micali G; Nardone B; West DP
    JAMA Dermatol; 2015 Jun; 151(6):600-6. PubMed ID: 25830296
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men.
    Walf AA; Kaurejo S; Frye CA
    Am J Mens Health; 2018 Jul; 12(4):900-906. PubMed ID: 29318957
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Re: inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
    Kaplan SA
    J Urol; 2014 Mar; 191(3):752. PubMed ID: 24522062
    [No Abstract]   [Full Text] [Related]  

  • 69. 5α-Reductase Inhibitors (5ARIs) and Male Reproduction.
    Drobnis EZ; Nangia AK
    Adv Exp Med Biol; 2017; 1034():59-61. PubMed ID: 29256127
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Atypical post-finasteride syndrome: A pharmacological riddle.
    Gupta AK; Sharma N; Shukla P
    Indian J Pharmacol; 2016; 48(3):316-7. PubMed ID: 27298504
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Oral Finasteride Presents With Sexual-Unrelated Withdrawal in Long-Term Treated Androgenic Alopecia in Men.
    Perez-Mora N; Velasco C; Bermüdez F
    Skinmed; 2015; 13(3):179-83. PubMed ID: 26380503
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis.
    Zhou Z; Song S; Gao Z; Wu J; Ma J; Cui Y
    Clin Interv Aging; 2019; 14():399-406. PubMed ID: 30863034
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia.
    Sato A; Takeda A
    J Dermatol; 2012 Jan; 39(1):27-32. PubMed ID: 21980923
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Assessing finasteride-associated sexual dysfunction using the FAERS database.
    Gupta AK; Carviel J; MacLeod MA; Shear N
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1069-1075. PubMed ID: 28300347
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Secondary infertility due to use of low-dose finasteride.
    Şalvarci A; Istanbulluoğlu O
    Int Urol Nephrol; 2013 Feb; 45(1):83-5. PubMed ID: 23070721
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.
    Wu M; Yu Q; Li Q
    Oncotarget; 2016 Dec; 7(50):82074-82084. PubMed ID: 27738338
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Finasteride 1 mg in alopecia: sexual dysfunction, suicidal ideation. Providing balanced information to male patients is key.
    Prescrire Int; 2016 Oct; 25(175):242. PubMed ID: 30688421
    [No Abstract]   [Full Text] [Related]  

  • 78. Finasteride in the treatment of men with frontal male pattern hair loss.
    Leyden J; Dunlap F; Miller B; Winters P; Lebwohl M; Hecker D; Kraus S; Baldwin H; Shalita A; Draelos Z; Markou M; Thiboutot D; Rapaport M; Kang S; Kelly T; Pariser D; Webster G; Hordinsky M; Rietschel R; Katz HI; Terranella L; Best S; Round E; Waldstreicher J
    J Am Acad Dermatol; 1999 Jun; 40(6 Pt 1):930-7. PubMed ID: 10365924
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Risk of Depression Associated With Finasteride Treatment.
    Pompili M; Magistri C; Maddalena S; Mellini C; Persechino S; Baldessarini RJ
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):304-309. PubMed ID: 33814544
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.